Tags

Type your tag names separated by a space and hit enter

Concise Review: MSC-Derived Exosomes for Cell-Free Therapy.
Stem Cells 2017; 35(4):851-858SC

Abstract

Mesenchymal stem cell transplantation is undergoing extensive evaluation as a cellular therapy in human clinical trials. Because MSCs are easily isolated and amenable to culture expansion in vitro there is a natural desire to test MSCs in many diverse clinical indications. This is exemplified by the rapidly expanding literature base that includes many in vivo animal models. More recently, MSC-derived extracellular vesicles (EVs), which include exosomes and microvesicles (MV), are being examined for their role in MSC-based cellular therapy. These vesicles are involved in cell-to-cell communication, cell signaling, and altering cell or tissue metabolism at short or long distances in the body. The exosomes and MVs can influence tissue responses to injury, infection, and disease. MSC-derived exosomes have a content that includes cytokines and growth factors, signaling lipids, mRNAs, and regulatory miRNAs. To the extent that MSC exosomes can be used for cell-free regenerative medicine, much will depend on the quality, reproducibility, and potency of their production, in the same manner that these parameters dictate the development of cell-based MSC therapies. However, the MSC exosome's contents are not static, but rather a product of the MSC tissue origin, its activities and the immediate intercellular neighbors of the MSCs. As such, the exosome content produced by MSCs appears to be altered when MSCs are cultured with tumor cells or in the in vivo tumor microenvironment. Therefore, careful attention to detail in producing MSC exosomes may provide a new therapeutic paradigm for cell-free MSC-based therapies with decreased risk. Stem Cells 2017;35:851-858.

Authors+Show Affiliations

Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida, USA.Longevity Therapeutics, Inc, La Jolla, California, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28294454

Citation

Phinney, Donald G., and Mark F. Pittenger. "Concise Review: MSC-Derived Exosomes for Cell-Free Therapy." Stem Cells (Dayton, Ohio), vol. 35, no. 4, 2017, pp. 851-858.
Phinney DG, Pittenger MF. Concise Review: MSC-Derived Exosomes for Cell-Free Therapy. Stem Cells. 2017;35(4):851-858.
Phinney, D. G., & Pittenger, M. F. (2017). Concise Review: MSC-Derived Exosomes for Cell-Free Therapy. Stem Cells (Dayton, Ohio), 35(4), pp. 851-858. doi:10.1002/stem.2575.
Phinney DG, Pittenger MF. Concise Review: MSC-Derived Exosomes for Cell-Free Therapy. Stem Cells. 2017;35(4):851-858. PubMed PMID: 28294454.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Concise Review: MSC-Derived Exosomes for Cell-Free Therapy. AU - Phinney,Donald G, AU - Pittenger,Mark F, Y1 - 2017/03/10/ PY - 2016/10/15/received PY - 2016/12/13/revised PY - 2017/01/02/accepted PY - 2017/3/16/pubmed PY - 2017/12/13/medline PY - 2017/3/16/entrez KW - Cellular therapy KW - Exosomes KW - Mesenchymal stem cells KW - Mesenchymal stromal cells KW - Microvesicles SP - 851 EP - 858 JF - Stem cells (Dayton, Ohio) JO - Stem Cells VL - 35 IS - 4 N2 - Mesenchymal stem cell transplantation is undergoing extensive evaluation as a cellular therapy in human clinical trials. Because MSCs are easily isolated and amenable to culture expansion in vitro there is a natural desire to test MSCs in many diverse clinical indications. This is exemplified by the rapidly expanding literature base that includes many in vivo animal models. More recently, MSC-derived extracellular vesicles (EVs), which include exosomes and microvesicles (MV), are being examined for their role in MSC-based cellular therapy. These vesicles are involved in cell-to-cell communication, cell signaling, and altering cell or tissue metabolism at short or long distances in the body. The exosomes and MVs can influence tissue responses to injury, infection, and disease. MSC-derived exosomes have a content that includes cytokines and growth factors, signaling lipids, mRNAs, and regulatory miRNAs. To the extent that MSC exosomes can be used for cell-free regenerative medicine, much will depend on the quality, reproducibility, and potency of their production, in the same manner that these parameters dictate the development of cell-based MSC therapies. However, the MSC exosome's contents are not static, but rather a product of the MSC tissue origin, its activities and the immediate intercellular neighbors of the MSCs. As such, the exosome content produced by MSCs appears to be altered when MSCs are cultured with tumor cells or in the in vivo tumor microenvironment. Therefore, careful attention to detail in producing MSC exosomes may provide a new therapeutic paradigm for cell-free MSC-based therapies with decreased risk. Stem Cells 2017;35:851-858. SN - 1549-4918 UR - https://www.unboundmedicine.com/medline/citation/28294454/Concise_Review:_MSC_Derived_Exosomes_for_Cell_Free_Therapy_ L2 - https://doi.org/10.1002/stem.2575 DB - PRIME DP - Unbound Medicine ER -